Free Trial

ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals logo
$16.75 +0.66 (+4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$16.73 -0.02 (-0.15%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRY vs. LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, and ADMA

Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

ARS Pharmaceuticals vs. Its Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

ARS Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 85.07%. Legend Biotech has a consensus price target of $74.18, suggesting a potential upside of 106.58%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than ARS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ARS Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92

ARS Pharmaceuticals has a net margin of -16.11% compared to Legend Biotech's net margin of -29.95%. ARS Pharmaceuticals' return on equity of -6.94% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
ARS Pharmaceuticals-16.11% -6.94% -5.60%
Legend Biotech -29.95%-21.19%-13.47%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 8 more articles in the media than Legend Biotech. MarketBeat recorded 14 mentions for ARS Pharmaceuticals and 6 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.44 beat ARS Pharmaceuticals' score of 0.97 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ARS Pharmaceuticals
5 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ARS Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARS Pharmaceuticals$89.15M18.45$8M-$0.16-104.69
Legend Biotech$627.24M10.52-$177.03M-$0.59-60.86

ARS Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.

Summary

ARS Pharmaceuticals beats Legend Biotech on 11 of the 17 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRY vs. The Competition

MetricARS PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.58B$2.42B$5.54B$8.87B
Dividend YieldN/A1.77%5.39%4.10%
P/E Ratio-104.688.7226.1719.90
Price / Sales18.45663.86414.67113.66
Price / Cash1,900.03151.5836.1356.90
Price / Book6.344.548.055.38
Net Income$8M$31.16M$3.15B$248.50M
7 Day Performance-2.95%0.15%1.85%2.97%
1 Month Performance15.84%8.81%4.81%6.02%
1 Year Performance93.42%2.55%34.86%20.39%

ARS Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRY
ARS Pharmaceuticals
2.9285 of 5 stars
$16.75
+4.1%
$31.00
+85.1%
+84.3%$1.58B$89.15M-104.6890Insider Trade
LEGN
Legend Biotech
3.34 of 5 stars
$33.85
-0.4%
$76.20
+125.1%
-21.1%$6.22B$627.24M-57.372,609Positive News
Analyst Forecast
TGTX
TG Therapeutics
3.7651 of 5 stars
$36.56
+1.5%
$40.80
+11.6%
+95.0%$5.80B$329M152.33290
GRFS
Grifols
4.1298 of 5 stars
$8.37
-4.6%
$10.30
+23.1%
+43.3%$5.75B$7.81B7.1523,822Analyst Downgrade
LNTH
Lantheus
4.4467 of 5 stars
$80.81
+2.0%
$130.50
+61.5%
-0.7%$5.59B$1.53B22.96700Positive News
TLX
Telix Pharmaceuticals
N/A$16.39
-4.4%
$22.00
+34.2%
N/A$5.54B$516.72M0.00N/AGap Down
High Trading Volume
NUVL
Nuvalent
3.7277 of 5 stars
$75.98
+1.3%
$115.50
+52.0%
+3.3%$5.46BN/A-17.3140Analyst Upgrade
Insider Trade
AXSM
Axsome Therapeutics
4.6769 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+27.1%$5.01B$385.69M-17.62380Analyst Revision
AKRO
Akero Therapeutics
3.6224 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+122.0%$4.31BN/A-27.7130
PCVX
Vaxcyte
1.7866 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-57.2%$4.29BN/A-8.33160News Coverage
Positive News
ADMA
ADMA Biologics
4.0975 of 5 stars
$17.87
+0.7%
$27.67
+54.8%
+54.8%$4.27B$426.45M21.02530

Related Companies and Tools


This page (NASDAQ:SPRY) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners